The novel drug approvals continue to rain down from the US FDA, with the agency's nod to Theravance Biopharma Inc. and Mylan NV's Yupelri (revefenacin) bringing the 2018 record-breaking total to 49.
Poseida Therapeutics Inc. picked up a regenerative medicine advanced therapy (RMAT) designation for its relapsed/refractory multiple myeloma treatment P-BCMA-101,...








